Adjuvant treatment with a symbiotic in patients with inflammatory non-allergic rhinitis.
Inflammatory non-allergic rhinitis (INAR) is characterized by the presence of an inflammatory infiltrate and a non-IgE-mediated pathogenesis. This retrospective, controlled, multicentre study investigated whether a symbiotic, containing Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo-oligosaccharides (Pollagen®, Allergy Therapeutics, Italy), prescribed as adjunctive therapy to a standard pharmacological treatment, was able to reduce symptom severity, endoscopic features, and nasal cytology in 93 patients (49 males and 44 females, mean age 36.3±7.1 years) with INAR. The patients were treated with nasal corticosteroid, oral antihistamine, and isotonic saline. At randomization, 52 patients were treated also with symbiotic as adjunctive therapy, whereas the remaining 41 patients served as controls. Treatment lasted for 4 weeks. Patients were visited at baseline, after treatment, and after 4-week follow-up. Adjunctive symbiotic treatment significantly reduced the percentages of patients with symptoms and endoscopic signs, and diminished inflammatory cells. In conclusion, the present study demonstrates that a symbiotic was able, as adjuvant treatment, to significantly improve symptoms, endoscopic feature, and cytology in patients with INAR, and its effect may be long lasting.
Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy.
M
M
Gelardi
Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy.
C
C
De Luca
Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy.
S
S
Taliente
Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy.
M L
ML
Fiorella
Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy.
N
N
Quaranta
U.O.C. of Otolaryngology  Ospedale Di Venere Carbonara di Bari, Italy.
C
C
Russo
Otolaryngology, Department of Sensory Organs, University Sapienza, Roma, Italy.
A
A
Ciofalo
ORL Clinic University of Insubriae, Varese, Italy.
A
A
Macchi
Section of Otolaryngology, Azienda Area Vasta Romagna-Riccione, Italy.
M
M
Mancini
Section of Otolaryngology, Ospedale Civico di Chivasso (TO), Italy.
P
P
Rosso
Otorhinolaryngology Unit, Department of Neuroscience, AOU Pisana, Pisa, Italy.
V
V
Seccia
Medical and Scientific Department Allergy Therapeutics Italia, Milan, Italy.
F
F
Guagnini
Department of Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) - Azienda Ospedaliera Universitaria San Martino - IST, Genoa, Italy.
G
G
Ciprandi
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000069982:Bifidobacterium animalis / Q000276:immunology*; D003131:Combined Modality Therapy / Q000379:methods; D003533:Cyproheptadine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007779:Lactobacillus acidophilus / Q000276:immunology*; D008297:Male; D000068656:Mometasone Furoate / Q000627:therapeutic use; D056692:Prebiotics / Q000008:administration & dosage; D019936:Probiotics / Q000008:administration & dosage*; D012189:Retrospective Studies; D012220:Rhinitis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000277:Adjuvants, Pharmaceutic; D000305:Adrenal Cortex Hormones; D006633:Histamine Antagonists; D056692:Prebiotics; D000068656:Mometasone Furoate; C103639:rupatadine; D003533:Cyproheptadine